https://charts.traderzeitung.de/phases/US89680M1018 string(1458) "{"isin":"US89680M1018","name":"TriSalus Life Sciences Inc","stock_id_xnas":32329719,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.92,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-1.6},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":5.71,"close_at":"2026-09-23 01:59:00","complete":true,"perf_pct":16.0569}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":5.79,"close_at":"2026-09-23 15:25:00","complete":true,"perf_pct":1.4011},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.995,"close_at":"2026-09-23 21:58:00","complete":true,"perf_pct":-13.7306},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.91,"close_at":"2026-09-23 23:42:00","complete":false,"perf_pct":-1.7017}]}]}"

TriSalus Life Sciences Aktie News & Nachrichten

[WKN: A3EP5W | Symbol: TLSI]

Realtimekurs

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über TriSalus Life Sciences gefunden werden.

TriSalus Life Sciences Nachrichtenticker öffnen

MT Newswires 23.09.2026 20:22 Uhr

Update: Aktien von TriSalus Life Sciences steigen nach Erhalt der FDA-Zulassung für TriNav Advance

02:21 PM EDT, 09/23/2026 (MT Newswires) -- (Updates with the latest stock move in the headline and the first paragraph.) Die Aktien von TriSalus Life

MT Newswires 22.09.2026 22:45 Uhr

Research-Alert: TriSalus Life Sciences erhält FDA-Zulassung für TriNav Advance

04:44 PM EDT, 09/22/2026 (MT Newswires) -- TriSalus Life Sciences (TLSI) teilte am späten Dienstag mit, dass das Unternehmen die Zulassung der US-amer